Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma

Abroad (travel likely)Recruiting

Conditions

Pheochromocytoma/Paraganglioma (PPGL)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
Contact: Study coordinator (Hongli Jing) · annsmile1976@sina.com · 18600586399

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

An Experimental Study of Belzutifan Impact on Catecholamine Metabolism

Pheochromocytoma and Paraganglioma (PPGL) · Pheochromocytoma Malignant · Pheochromocytoma, Metastatic

Abroad (travel likely)RecruitingPHASE2

Cambridge, United Kingdom

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Sarcoma · Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC) · Mesothelioma

Abroad (travel likely)RecruitingPHASE2

Bethesda, United States

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Pheochromocytoma/Paraganglioma · Pancreatic Neuroendocrine Tumor · Von Hippel-Lindau Disease

IsraelRecruitingPHASE2

Los Angeles, United States · Chicago, United States